Conference Coverage From EASL

[Guest guest]

INDEPENDENT CONFERENCE COVERAGE

2011 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art

medical information to healthcare professionals through conference coverage and

other educational programs.

CLICK TO ACCESS

Conference Coverage From Berlin, Germany

CCO's Independent Conference Coverage of EASL 2011 in Berlin, Germany, includes

Capsule Summaries of the most clinically relevant data presented at the meeting,

an original CCO highlights slideset, and a CME-certified Expert Analysis.

To browse available coverage, click here or select a link below.

Capsule Summaries:

Capsule Summaries are “quick read” reviews of key oral and poster presentations,

handpicked by leading experts in hepatology. The comprehensive contents are

based on the actual data presented at the meeting—providing the most up-to-date

information.

CLICK TO ACCESS

From Podium to Practice: Clinical Impact of New Data From EASL 2011

Click a link below to access Capsule Summaries

Addition of Alisporivir to PegIFN/RBV Yields Superior Efficacy vs PegIFN/RBV

Alone in Treatment-Naive Patients With Genotype 1 HCV – Link

Previous Treatment Response Categorization Better Predictor of SVR Following

Telaprevir-Based Therapy Than Response to 4-Week PegIFN/RBV Lead-in Phase – Link

Boceprevir Plus PegIFN/RBV Safe and Effective in Genotype 1 HCV–Infected

Patients With Advanced Fibrosis/Cirrhosis – Link

Telaprevir-Resistant HCV Variants Present at Time of Treatment Failure Replaced

by Wild-Type Virus Over Time in Majority of Patients – Link

Among 1 Genotype HCV–Infected Patients Not Achieving SVR With Boceprevir-Based

Regimen, Resistance-Associated Variants More Common in Those With Poor Response

to 4-Week PegIFN/RBV Lead-in – Link

PSI-938 and PSI-7977 Purine and Pyrimidine Nucleotide Analogues Demonstrate

Favorable Safety/Tolerability and Robust 14-Day Antiviral Activity Alone and in

Combination Against Genotype 1 HCV – Link

ASPIRE Interim Data: TMC435 Plus PegIFN/RBV Demonstrates High Rates of Response

Through Week 24 in Patients With Genotype 1 HCV Who Failed Previous PegIFN/RBV –

Link

This Conference Coverage is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Coming Soon: CME-Certified Expert Analysis

2011 Annual Meeting of the European Association for the Study of the Liver

Leading experts discuss the most clinically relevant data from the meeting in

Berlin, Germany, in a CME-certified Expert Analysis.

This program is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Berlin%202011.aspx

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and

Clinical Care Options, LLC.

Supported by educational grants from Bristol-Myers Squibb; Pharmasset, Inc.; and

Vertex.

Clinical Care Options Hepatitis

GET MORE FROM CCO

2011 Annual CCO HIV and Hepatitis C Symposium

Register today for the 2011 Annual CCO HIV and Hepatitis C Symposium for a

review of the most important scientific and clinical advances over the past

year, including expert guidance on integrating novel HCV agents into clinical

care.

Click here for more information.

Conference Coverage

Journal Options

Management Series

Treatment Updates

Interactive Cases

Live Meetings

RSS / Podcasts

My CME Tracker

Free Bookstore

Slide Downloads

Copyright 2011 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

To ensure you receive Clinical Care Options educational materials by email,

please add info@... to your contacts or address book.

Not a member yet? Click here